Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.
Also called NCT00987415
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 253 participants
- Registry
-
NCT00987415
-
- Other papers using this trial's data
- Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT00987415. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2014-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
- Acronym
- EXACT-HF
- Condition
- Heart Failure
- Condition
- Elevated Serum Uric Acid
- Intervention (Drug)
- allopurinol
- Intervention (Drug)
- sugar pill
- Lead sponsor
- Duke University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct00987415- Content hash
9786d12308958d751e4c41bdf5583a41349d1b01023266643b8528f7fa642b19